Skip to main content
Top
Published in: Medical Oncology 1/2019

01-01-2019 | Original Paper

Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer

Authors: B. A. Jereczek-Fossa, A. Maucieri, G. Marvaso, S. Gandini, C. Fodor, D. Zerini, G. Riva, O. Alessandro, A. Surgo, S. Volpe, G. Fanetti, S. Arculeo, M. A. Zerella, S. Parisi, P. Maisonneuve, A. Vavassori, F. Cattani, R. Cambria, C. Garibaldi, A. Starzyńska, G. Musi, O. De Cobelli, M. Ferro, F. Nolè, D. Ciardo, R. Orecchia

Published in: Medical Oncology | Issue 1/2019

Login to get access

Abstract

To report toxicity and efficacy outcome of moderately hypofractionated image-guided external-beam radiotherapy in a large series of patients treated for prostate cancer (PCa). Between 10/2006 and 12/2015, 572 T1-T3N0M0 PCa patients received 70.2 Gy in 26 fractions at 2.7 Gy/fraction: 344 patients (60%) with three-dimensional conformal radiotherapy (3D-CRT) and 228 (40%) with intensity-modulated radiotherapy (IMRT). Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria and Houston definition (nadir + 2) were used for toxicity and biochemical failure evaluation, respectively. Median age was 74 years (interquartile range 69–77). Compared with 3D-CRT, in IMRT group more high-risk patients (29% vs 18%; P = 0.002) and more high-volume target (75% vs 60%; P < 0.001) were included. Acute gastro-intestinal (GI) toxicity G > 1 were registered in 8% and in 11% IMRT and 3D-CRT patients, respectively, whereas late GI G > 1 were observed in 2% and 16% IMRT and 3D-CRT patients, respectively. Acute genito-urinary (GU) toxicity G > 1 were registered in 26% and 40% IMRT and 3D-CRT patients, respectively, whereas late GU G > 1 occurred in 5% IMRT and 15% 3D-CRT patients. Multivariate proportional hazard Cox models confirmed significantly greater risk of late toxicity with 3D-CRT compared to IMRT for GU > 1 (P = 0.004) and for GI > 1 (P < 0.001). With a median 4-year follow-up, overall survival (OS), clinical progression-free survival (cPFS) and biochemical PFS (bPFS) for the whole series were 91%, 92% and 91%, respectively. cPFS and bPFS were significantly different by risk groups. Multivariate Cox models for bPFS and cPFS showed no difference between irradiation techniques and a significant impact of risk group and initial PSA. Moderately hypofractionated radiotherapy is a viable treatment option for localized PCa with excellent tumour control and satisfactory toxicity profile. IMRT seems associated with a reduction in toxicity, whereas tumour control was equal between IMRT and 3D-CRT patients and depended mainly on the risk category.
Literature
7.
go back to reference Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68:1424–30.CrossRef Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68:1424–30.CrossRef
11.
go back to reference Jean-Pierre P, Stoyanova R, Penedo F, et al. Treatment-related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity modulated radiotherapy: a phase III hypofractionation trial. Int J Radiat Oncol Biol Phys. 2011;81:667.CrossRef Jean-Pierre P, Stoyanova R, Penedo F, et al. Treatment-related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity modulated radiotherapy: a phase III hypofractionation trial. Int J Radiat Oncol Biol Phys. 2011;81:667.CrossRef
15.
go back to reference ICRU. Report 62: prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). Bethesda: International Commission on Radiation Units and Measurements; 1999. ICRU. Report 62: prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). Bethesda: International Commission on Radiation Units and Measurements; 1999.
21.
go back to reference Roach M III, Hanks G, Thames T Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974. https://doi.org/10.1016/j.ijrobp.2006.04.029. Roach M III, Hanks G, Thames T Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974. https://​doi.​org/​10.​1016/​j.​ijrobp.​2006.​04.​029.
23.
go back to reference Eade TN, Hanlon AL, Horwitz EM, et al. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys. 2007;68(3):682–9.CrossRef Eade TN, Hanlon AL, Horwitz EM, et al. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys. 2007;68(3):682–9.CrossRef
Metadata
Title
Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer
Authors
B. A. Jereczek-Fossa
A. Maucieri
G. Marvaso
S. Gandini
C. Fodor
D. Zerini
G. Riva
O. Alessandro
A. Surgo
S. Volpe
G. Fanetti
S. Arculeo
M. A. Zerella
S. Parisi
P. Maisonneuve
A. Vavassori
F. Cattani
R. Cambria
C. Garibaldi
A. Starzyńska
G. Musi
O. De Cobelli
M. Ferro
F. Nolè
D. Ciardo
R. Orecchia
Publication date
01-01-2019
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2019
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-018-1233-1

Other articles of this Issue 1/2019

Medical Oncology 1/2019 Go to the issue